These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 17216681

  • 21. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E.
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [Abstract] [Full Text] [Related]

  • 22. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y, Wong M, Thiebaud D, Stock JL.
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [Abstract] [Full Text] [Related]

  • 23. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL.
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [Abstract] [Full Text] [Related]

  • 24. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P, Hamdy NA, Zwinderman AH, Ballieux BE, Papapoulos SE.
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [Abstract] [Full Text] [Related]

  • 25. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
    Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML.
    Arch Intern Med; 2004 May 24; 164(10):1108-12. PubMed ID: 15159268
    [Abstract] [Full Text] [Related]

  • 26. Relationship between osteoporosis and cardiovascular disease in postmenopausal women.
    Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR.
    J Bone Miner Res; 2005 Nov 24; 20(11):1912-20. PubMed ID: 16234963
    [Abstract] [Full Text] [Related]

  • 27. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH.
    Arthritis Rheum; 2004 Dec 24; 50(12):4028-34. PubMed ID: 15593198
    [Abstract] [Full Text] [Related]

  • 28. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
    Scharla S, Oertel H, Helsberg K, Kessler F, Langer F, Nickelsen T.
    Curr Med Res Opin; 2006 Dec 24; 22(12):2393-402. PubMed ID: 17257453
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH.
    Arch Intern Med; 2004 Oct 11; 164(18):2024-30. PubMed ID: 15477438
    [Abstract] [Full Text] [Related]

  • 32. A multicentre, retrospective case-control study assessing the role of trabecular bone score (TBS) in menopausal Caucasian women with low areal bone mineral density (BMDa): Analysing the odds of vertebral fracture.
    Rabier B, Héraud A, Grand-Lenoir C, Winzenrieth R, Hans D.
    Bone; 2010 Jan 11; 46(1):176-81. PubMed ID: 19747992
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep 11; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 37. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH.
    J Bone Joint Surg Am; 2009 Jun 11; 91(6):1329-38. PubMed ID: 19487509
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J, Vanuga P, Payer J, Svobodník A.
    Vnitr Lek; 2008 Mar 11; 54(3):217-9, 221-4. PubMed ID: 18522288
    [Abstract] [Full Text] [Related]

  • 40. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.
    Curr Med Res Opin; 2005 Sep 11; 21(9):1441-52. PubMed ID: 16197663
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.